About this episode

This episode discusses the Phase 3 trial of Atacicept for treating IgA Nephropathy with guest Jonathan Barratt.

The Filtrate Joel Topf ‍ ‍ @kidneyboy.bsky.social‬ ( COI ) Sophia Ambruso @sophia-kidney.bsky.social Swapnil Hiremath @hswapnil.medsky.social and on LinkedIn Special Guests Jonathan Barratt Professor of Renal Medicine, University of Leicester Google Scholar (COI: all the companies) Editing and Show Notes by Nayan Arora @captainchloride.bsky.social The Kidney Connection written and performed by Tim Yau Show Notes Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy (Aliza Thompson, 2019 PubMed ) The number, quality, and coverage of randomized controlled trials in nephrology ( PubMed 2004 ) Updated here ( PubMed | NephJC discussion ) A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction ( PubMed 2017 ) BLISS Belimumab in lupus nephritis ( NephJC | PubMed ) The Phase 2 trial of atacicept A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy ( PubMed ) The phase 3 trial of atacicept, the subject of this podcast A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy ( PubMed | NephJC ) Christos’ Bluesky post…

More episodes of Freely Filtered, a NephJC Podcast

• FF91 Liberate-D · March 30, 2026 · 1h 36m
• FF90 NephMadness 2026: Animal House · March 21, 2026 · 1h 25m
• FF 89 Top Stories of 2025 · January 31, 2026 · 1h 51m
• FF 86 Atacicept for IgAN. Third attempt · December 28, 2025 · 1h 15m
• FF 88 BICARICU-2, Bicarbonate in the ICU, still not helpful? · December 27, 2025 · 1h 25m
• FF 87 Can Fish Oil Knock the Crap out of Dialysis Associated CV Disease? · December 14, 2025 · 1h 20m

Explore listener stats, chart rankings, contacts and more on the Freely Filtered, a NephJC Podcast podcast page.